Kamlesh Ansingkar, MD
Family Medicine · Columbus, GANPI 1184787327
Payments from drug & device makers
Across 602 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$1K
- GSK$914
- Bayer$856
- plus $4K from 29 others
What the payments were for
- Food & beverage$10,597100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 85 | $1,665 |
| Novo Nordisk | 97 | $1,452 |
| Boehringer Ingelheim | 58 | $1,127 |
| Lilly USA, LLC | 81 | $1,090 |
| GSK | 51 | $914 |
| Bayer | 35 | $856 |
| Abbott | 24 | $481 |
| Astellas Pharma US Inc | 21 | $460 |
| Sanofi-aventis U.S. LLC | 21 | $379 |
| Pfizer | 24 | $353 |
| Amgen | 20 | $344 |
| AbbVie(2 entities) | 18 | $289 |
| Johnson & Johnson | 16 | $260 |
| Otsuka America Pharmaceutical, Inc. | 6 | $138 |
| Merck | 7 | $117 |
| Esperion Therapeutics, Inc. | 6 | $103 |
| Sumitomo Pharma America, Inc. | 3 | $76 |
| Novartis | 3 | $64 |
| Idorsia Pharmaceuticals US Inc | 4 | $63 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $45 |
| Dexcom, Inc. | 2 | $39 |
| Philips North America LLC | 2 | $30 |
| Zyla Life Sciences, Inc. | 2 | $26 |
| Vertex | 1 | $22 |
| Braemar Manufacturing, LLC | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Intuitive Surgical | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| RTI Surgical, Inc | 1 | $16 |
| Abiomed | 1 | $15 |
| Alvogen Inc | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$10,603 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 194 | $242,858 |
| OzempicSemaglutide | 141 | $181,644 |
| FarxigaDapagliflozin Propanediol | 121 | $150,576 |
| EliquisApixaban | 98 | $140,107 |
| MounjaroTirzepatide | 81 | $120,154 |
| TrulicityDulaglutide | 57 | $117,504 |
| JanuviaSitagliptin Phosphate | 46 | $58,244 |
| RybelsusSemaglutide | 18 | $39,773 |
| LinzessLinaclotide | 27 | $34,595 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $34,569 |
| MyrbetriqMirabegron | 19 | $23,372 |
| VascepaIcosapent Ethyl | 19 | $20,208 |
| RexultiBrexpiprazole | 13 | $19,617 |
| Diclofenac Sodium | 239 | $19,195 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $17,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,127 | $242,858194 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,090 | $237,658138 claims |
| Novo NordiskOzempic, Rybelsus | $1,452 | $221,417159 claims |
| AstraZenecaFarxiga, Symbicort | $1,665 | $163,101144 claims |
| PfizerEliquis | $353 | $140,10798 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy | $914 | $67,773102 claims |
| MerckJanuvia | $117 | $58,24446 claims |
| AbbVieLinzess | $289 | $34,59527 claims |
| Astellas Pharma US IncMyrbetriq | $460 | $23,37219 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $138 | $19,61713 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $76 | $5,20811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Columbus
- Joseph SurberColumbus$16.6M
- Jeffrey KingsleyColumbus$8.1M
- Bantwal BaligaColumbus$117K
- Megbewe OkorobaColumbus$61K
- Kimberly Brown-GullattColumbus$35K
- Angela RitterGainesville$15.8M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.